Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cipla Rumored Frontrunner For Wockhardt Deal

In ‘Pole Position’ To Buy Parts Of Debt-Laden Wockhardt

Executive Summary

Cipla is reportedly leading the pack to acquire business divisions of debt-laden Wockhardt in a transaction that could be worth hundreds of millions of dollars and would boost the Mumbai-based company’s domestic presence.

You may also be interested in...



Cipla Rationalizes Sri Lanka Operations

Looking to rationalize its Sri Lankan operations, Cipla buys 40% stake held by joint venture partner Citihealth Imports in Cipla Pharma Lanka. Wholly-owned subsidiary Breathe Free Sri Lanka will be its vehicle for growth in the country.

Bids Rumored For Stake In Wockhardt

A clutch of domestic suitors and global private-equity funds are conducting due diligence with an eye to acquiring segments of debt-laden Indian firm Wockhardt and bids are expected in late November, according to a new report.

Momentum Is Back At Cipla In Q2

Cipla had a strong run across key businesses in Q2, with products like generic Sensipar retaining share in the US despite stiff competition. But launch timelines for generic albuterol in the US have been pushed back to fiscal 2021.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB149406

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel